

FIG. 1A/1B



1A



1B

FIG. 1C



Vehicle
Composition 3 200 μg/ml
Composition 3 400 μg/ml
Cell viability (%)
2.0
1.5
1.0
0.5
0.0
***
**
***
***
**
#
##
###
###
###
###
###
###
0
0.1
1
10
Gefitinib (μM)

FIG. 2



Cell viability (% control)
1.5
1.0
0.5
0.0
24 hrs
48 hrs
72 hrs
AM-decoction-H2O (mg/ml) - 10 0 10
Cisplatin (μM) - - 20 20

FIG. 3A



Hoechst
2.7 %
AM-decoction-H2O
100 µg/ml
0.6 %
AM-decoction-DMSO
100 µg/ml
1.0 %
Composition 4
200 µg/ml
0.5 %
Composition 5
200 µg/ml
0.8 %
Hoechst Blue-A
Hoechst Red-A
(X 1,000)

FIG. 3B





CL97
SP cell number (% Control)
Cell viability (% control)
150
100
50
0
Verapamil (μM) - 100 - -
Composition 3 (μg/ml) - - 100 200
CL141
SP cell number (% Control)
Cell viability (% control)
Verapamil (μM) - 100 - -
Composition 3(μg/ml) - - 100 200
H441
SP cell number (% Control)
Cell viability (% control)
Verapamil (μM) - 100 - -
Composition 3(μg/ml) - - 100 200

FIG. 4A/B


Composition 3
Control
Brand A
Brand B
Brand C
Brand D
Brand E
Number of colonies (% control)
150
100
50
0
Control
Brand A
Brand B
Brand C
Brand D
Brand E
BZ-EtOH
Control
Brand A
Brand B
Brand C
Brand D
Brand E
Number of colonies (% control)
150
100
50
0
Control
Brand A
Brand B
Brand C
Brand D
Brand E


4A 4B

FIG. 4C/D



Composition 3
0
200
400
(µg/ml)
Number of colonies (% Control)
150
100
50
0
**
***
Composition 3 (µg/ml)
-
200
400
Composition 3
Control
Batch A
Batch B
Batch C
Batch D
Batch E
Number of colonies (% Control)
150
100
50
0
Control
Batch A
Batch B
Batch C
Batch D
Batch E

4C 4D

FIG. 5A/B



CL97
CL97 sphere
CL141
CL141 sphere

5A



CL97
CL97 sphere
CL141
CL141 sphere
CD133
CD44
Oct4
Nanog
β-actin

5B

FIG. 5C/D


CL97
Cell viability (% control)
150
100
50
0
Composition 3 (µg/ml)
-
100
200
400
CL97 sphere
Spheroid cell number (% Control)
150
100
50
0
**
**
***
-
100
200
400


5C



CL141
Cell viability (% control)
150
100
50
0
Composition 3 (µg/ml)
-
100
200
400
CL141 sphere
Spheroid cell number (% Control)
150
100
50
0
**
**
***
-
100
200
400

5D

FIG. 6A-C

6A





6B



6C






FIG. 7A/B



FL4-H::FL4-H


7A




FL4-H::FL4-H

7B

FIG. 8A/B



IL-1β (pg/ml)
1600
1200
800
400
0
LPS - + - - - - - - - -
AM-decoction-DMSO (μg/ml) - - 0.1 1 2 5 - - - -
Composition 4 (μg/ml) - - - - - - 0.1 1 2 5

8A



IL-1β (pg/ml)
1600
1200
800
400
0
LPS - + + + + + + + + +
AM-decoction-DMSO (μg/ml) - - 0.1 1 2 5 - - - -
Composition 4 (μg/ml) - - - - - - 0.1 1 2 5

8B

FIG. 8C/D


TNF-α (pg/ml)
1600
1200
800
400
0
LPS
AM-decoction-DMSO (μg/ml)
Composition 4 (μg/ml)
0.1 1 2 5
0.1 1 2 5

8C


TNF-α (pg/ml)
1600
1200
800
400
0
LPS
AM-decoction-DMSO (μg/ml)
Composition 4 (μg/ml)
0.1 1 2 5
0.1 1 2 5

8D

FIG. 9A-C





A
Control
Composition 3 400 µg/ml
Composition 3 600 µg/ml
Sorafenib 10 µM
B
Tube number %
150
100
50
0
**
Composition 3 (µg/ml)
-
400
600
C
Tube number %
150
100
50
0
**
Sorafenib (µM)
-
10

FIG. 10A/B



10A



10B

FIG. 10C



Tumor size
(Fold change related to week 1)
120
100
80
60
40
20
0
1
2
3
4
5
6
7
8
9
10
Time (weeks)
Comtrol
Gefitinib
Composition 1
Composition 1 + Gefitinib
Composition 2
Composition 2 + Gefitinib
Composition 3
Composition 3 + Gefitinib

FIG. 11



(KDa)
175
98
37
p-EGFR
p-β catenin
GAPDH
EGFR
β catenin
GAPDH
Control-1
Composition 1 -1
Composition 1 -2
Composition 1 -3
Composition 1 -4
Composition 1 -5
Composition 1 +G-1
Composition 1 +G-2
Composition 1 +G-3
Composition 1 +G-4
Composition 1 +G-5
Composition 3 -1
Composition 3 -2
Composition 3 -3
Composition 3 -4
Composition 3 -5
Composition 3 +G-1
Composition 3 +G-2
Composition 3 +G-3
Composition 3 +G-4
Composition 3 +G-5
Composition 2 -1
Composition 2 -2
Composition 2 -3
Composition 2 -4
Composition 2 -5
Composition 2 +G-1
Composition 2 +G-2
Composition 2 +G-3
Composition 2 +G-4
Composition 2 +G-5
Control-1
Control-2
Control-3
Control-4
Control-5
Gefitinib-1
Gefitinib-2
Gefitinib-3
Gefitinib-4
Gefitinib-5

FIG. 12A/B




(A) Progression-free survival
n
Median survival
C/T
21
150
C/T+YQ1
38
180
P=0.0224, 95% CI: 0.6568 to 1.776
Hazard Ratio: 0.4541
Progression Free Survival (%)
100
80
60
40
20
0
0 100 200 300 400 500 600 700 800 900 1000
Day
(B) Overall survival
n
Median survival
C/T
21
284
C/T+YQ1
38
641
P=0.0006, 95% CI: 1.699 to 2.816
Hazard Ratio: 0.2795
Overall Survival (%)
100
80
60
40
20
0
0 150 300 450 600 750 900 1050 1200 1350 1500
Day

FIG. 12C/D


(C) Overall survival in Adenocarcinoma
n
Median survival
C/T
15
161
C/T+YQ1
28
644
P =0.0004, 95% CI: 4.737 to 5.747
Hazard Ratio: 0.1915
Overall Survival (%)
100
80
60
40
20
0
0 150 300 450 600 750 900 1050 1200 1350 1500
Day



(D) Overall survival in Non-Adenocarcinoma
n
Median survival
C/T
6
221
C/T+YQ1
10
209.5
P=0.5417, 95% CI: 0.6010 to 1.295
Hazard Ratio: 0.7086
Overall Survival (%)
100
80
60
40
20
0
0 110 220 330 440 550 660 770 880 990 1100
Day

FIG. 12E/F



(E) Wild type Overall survival
n
Median survival
C/T 13 117
C/T+YQ1 21 198
P=0.0137, 95% CI: 1.207 to 2.178
Hazard Ratio: 0.3392
Overall Survival (%)
100
80
60
40
20
0
0 150 300 450 600 750 900 1050 1200 1350 1500
Day
(F) Mutation(+) Overall survival
n
Median survival
C/T 6 374
C/T+YQ1 15 971
P=0.0063, 95% CI: 2.261 to 2.931
Hazard Ratio: 0.09884
Overall Survival (%)
100
80
60
40
20
0
0 150 300 450 600 750 900 1050 1200 1350 1500
Day

FIG. 12G



(G) After first-line therapy survival (after RECIST-PD survival)
n
Median survival
C/T
18
131
C/T+YQ1
32
370
P=0.0142, 95% CI: 2.303 to 3.346
Hazard Ratio: 0.3748
Overall Survival (%)
100
80
60
40
20
0
0 120 240 360 480 600 720 840 960 1080 1200
Day

FIG. 13



Lung cancer patients
Control subjects
MNC CD11b-14/CD68 01 .001
MNC CA CD11b-14/CD68 01 .001
MNC NC CD11b-14/iNOS 01 .004
CD14-CY5
CD11b PE
R4
% CD11b+/CD14-
18.43
26.10
6.31

FIG. 14



P<0.01
P<0.01
P<0.03
p=N/A
P<0.03
CD11b+/CD14- (%)
100
90
80
70
60
50
40
30
20
10
0
Rx naive
Control
PostOP (-)
PostOP (+)
SD+PR+CR
PD
Lung cancer patient subsets

FIG. 15




p<0.05
P<0.05
P=0.67
p=N/A
P<0.05
Monocytes (M1/M2 ratio)
13
12
11
10
9
8
7
6
5
4
3
2
1
0
Rx naive
Control
PostOP (-)
PostOP (+)
SD+PR+CR
PD
Lung cancer patient subsets

FIG. 16


p<0.01
P<0.05
P<0.01
p=N/A
P<0.03
CD3+/CD8+ (%)
50
40
30
20
10
0
Rx naive
Control
PostOP (-)
PostOP (+)
SD+PR+CR
PD
Lung cancer patient subsets